In the landscape of modern drug discovery, the traditional animal study has long been the bedrock of safety assessment. However, a quiet revolution is underway, fueled not by the creation of new laboratory models, but by the intelligent exploitation of data that has been sitting in storage for decades. Digital pathology, once a niche convenience born of pandemic-era necessity, has matured into a powerful engine for reducing reliance on animal testing, offering a path to "mine" historical tissue samples to answer future scientific questions.
The Paradigm Shift: From Disposable Slides to Digital Data
For generations, the workflow of a pathologist was linear and terminal. A tissue sample was harvested, processed, stained, and examined under a microscope. The pathologist recorded their findings, and the glass slide was consigned to a dark archive, effectively becoming a one-way street of data consumption.
“Before, the pathology endpoint was just a report,” explains Aleksandra Zuraw, DVM, PhD, a veterinary pathologist at Charles River Laboratories. “Now, you have the digitized slide, which is pixels. That transition from physical glass to high-resolution digital data is the catalyst for everything that follows.”
This shift is transformative. By digitizing slides, researchers are no longer limited to the initial observation. These images can be processed through machine learning models capable of detecting subtle, complex patterns—including molecular signatures—that remain invisible to the human eye. The slide is no longer a static snapshot; it is a dynamic data source that can be queried repeatedly as new diagnostic technologies emerge.
Chronology of a Transformation
The movement toward digital pathology and alternative methods has accelerated significantly over the last several years, driven by both technological capability and regulatory pressure.
- 2020–2021: The COVID-19 pandemic forces global pathology departments to transition to remote workflows. Digital slide scanning becomes a necessity, creating the first massive, standardized libraries of high-resolution digitized tissue.
- 2022: The enactment of the FDA Modernization Act 2.0 signals a landmark shift in US policy, legally allowing for non-animal methods to support drug trial applications.
- 2024: Charles River Laboratories launches its "Alternative Methods Advancement Project," a systematic effort to integrate digital pathology and virtual controls into standard preclinical safety protocols.
- 2025: The OECD releases guidance on sample collection for "omics" analysis, providing a framework for how archived formalin-fixed, paraffin-embedded (FFPE) tissue can be used for sophisticated molecular investigations.
- 2026: The FDA releases updated regulations and a comprehensive roadmap aimed at phasing out traditional animal testing for monoclonal antibodies, signaling a long-term shift toward New Approach Methodologies (NAMs) as the industry default.
Leveraging the Past: Virtual Controls and Archived Tissue
One of the most immediate ways to reduce animal usage is the implementation of "virtual control groups." In standard toxicology studies, a significant number of animals are utilized purely as controls to provide a baseline for comparison. By leveraging robust, historical databases of previous studies, researchers can replace these control animals with high-quality, matched data.
"Control animals are always a big fraction of every study," Dr. Zuraw notes. "By generating enough matched data to provide virtual controls, we are effectively cutting the number of animals required by simple arithmetic."
Beyond virtual controls, the industry is rediscovering the immense value of FFPE blocks. When a research question arises after an animal study has concluded—such as the need to investigate a specific biomarker or protein expression—scientists often previously had to initiate a new study. Today, they can return to the archives. If the initial tissue was preserved correctly, it holds a wealth of molecular information that remains relevant long after the original study has ended. This allows researchers to answer new, complex questions without the need for additional animal experimentation.
Supporting Data: The Power of Computational Pathology
The efficacy of these methods is supported by the increasing precision of digital analysis. A core area of development is molecular prediction from hematoxylin and eosin (H&E) stained slides. This technique uses AI to predict molecular and genetic characteristics directly from standard staining, potentially bypassing the need for secondary, invasive testing.
Furthermore, the rise of "virtual staining" represents the next frontier. By using scanners to capture unstained tissue and software to generate the appearance of a stain, labs are moving toward a workflow that may eventually eliminate the need for physical glass slides altogether. As these methodologies become more standardized, the "snowball effect" described by Dr. Zuraw suggests that the barrier to entry for digital adoption is lowering, inviting smaller labs to join the shift.
Official Responses and Regulatory Trajectory
The FDA’s current stance is clear: the goal is to make animal studies the exception rather than the norm. The 2025–2026 roadmap serves as a directive for the pharmaceutical industry to move away from legacy practices. By focusing first on biologics like monoclonal antibodies, the agency is establishing a template for success that can be applied to chemical entities in the coming years.
Regulatory bodies are not just permitting these changes; they are actively encouraging them through updated guidance on sample preparation. The key, however, remains the transition from theory to practice. As Dr. Zuraw emphasizes, "You still need enough early adopters to generate precedent. Those early adopters will embrace the guidance, figure it out, and troubleshoot, and then others can build on their work without reinventing the wheel."
Implications: A More Ethical and Efficient Future
The implications of this shift are profound, touching on ethics, cost, and scientific accuracy.
- Animal Welfare: By reducing the number of animals required for control groups and avoiding redundant studies through the re-analysis of archived tissue, the industry is making a measurable leap in ethical research standards.
- Scientific Depth: Moving from a "one-and-done" report to a model where data is re-queried allows for a deeper, more granular understanding of drug toxicity and efficacy. It turns archival storage into a living library of biological knowledge.
- Economic Efficiency: While the upfront investment in digital scanning and AI infrastructure is significant, the long-term reduction in animal housing, maintenance, and the need for repetitive experimental cycles offers a compelling economic argument for the industry.
- Data Integrity: Digital pathology allows for easier sharing of data between researchers and regulatory agencies. A digital file is more robust, searchable, and collaborative than a physical box of glass slides.
As we look toward the next decade, the integration of digital pathology into the mainstream of preclinical research seems inevitable. The "old tissue" that was once considered a stagnant resource is now being re-evaluated as a cornerstone of the future. Through the combination of AI, regulatory support, and a commitment to innovation, the drug discovery industry is proving that sometimes the best way to move forward is to look back at the data we have already collected.
About the Author
